K.G. Jebsen Centre for Alzheimer's Disease

K.G. Jebsen Centre for Alzheimer's Disease
Name	K.G. Jebsen Centre for Alzheimer's Disease
Established	2012
Focus	Alzheimer's disease research
Headquarters	Bergen, Norway
Affiliation	University of Bergen
Director	Kristian Steen Frederiksen

K.G. Jebsen Centre for Alzheimer's Disease is a dedicated research center focused on advancing the understanding and treatment of Alzheimer's disease. Established at the University of Bergen in Norway, it operates with significant support from the K.G. Jebsen Foundation. The centre integrates clinical and basic science to investigate disease mechanisms, with the ultimate goal of developing effective therapeutic strategies and improving patient care.

History and establishment

The centre was founded in 2012 following a major grant from the K.G. Jebsen Foundation, a philanthropic organization established by Norwegian businessman Kjell Inge Røkke. Its creation was part of a broader national initiative, the K.G. Jebsen Medical Research Centres, designed to bolster cutting-edge biomedical research across Norway. The establishment at the University of Bergen leveraged the institution's longstanding expertise in neuroscience and its affiliation with the Haukeland University Hospital. This strategic placement within the Western Norway Regional Health Authority ensured a direct pipeline between laboratory discovery and clinical application, addressing a critical need for focused research on dementia.

Research focus and objectives

The centre's primary scientific mission is to elucidate the early pathological mechanisms of Alzheimer's disease, with a particular emphasis on the pre-symptomatic phase. A core objective is to identify and validate novel biomarkers for early detection, utilizing advanced techniques in neuroimaging and cerebrospinal fluid analysis. Researchers investigate the complex interplay between amyloid beta and tau protein pathologies, as well as the role of neuroinflammation and vascular dysfunction in disease progression. The overarching aim is to translate these fundamental discoveries into targeted interventions that can delay or prevent the onset of clinical symptoms.

Organizational structure and leadership

The centre operates as an integrated unit within the Faculty of Medicine at the University of Bergen. It is led by a director, a position held by Professor Kristian Steen Frederiksen. Scientific activities are organized into interdisciplinary research groups, often co-led by principal investigators specializing in neurology, molecular biology, and neuropsychology. These groups work in close conjunction with the clinical research facilities at Haukeland University Hospital and the Norwegian National Advisory Unit on Ageing and Health. An external scientific advisory board, comprising international experts like John Hardy and Bruno Dubois, provides strategic guidance and evaluation.

Key research projects and findings

A flagship project is the ongoing Bergen Alzheimer's Disease Research Study, a longitudinal cohort study tracking individuals from subjective cognitive decline to mild impairment. This work has contributed significant data on the predictive value of MRI and PET scan biomarkers. Researchers have published findings in journals such as The Lancet Neurology on the dynamics of tau protein spread in the brain. Another major project investigates genetic risk factors in the Norwegian population, building on genome-wide association studies to identify variants linked to apolipoprotein E. The centre also conducts clinical trials, testing potential therapies targeting amyloid beta clearance and cognitive training protocols.

Collaborations and partnerships

The centre maintains an extensive network of national and international collaborations. It is a key node in the European Alzheimer's Disease Consortium and participates in global initiatives like the Alzheimer's Disease Neuroimaging Initiative. Within Scandinavia, it partners with the Karolinska Institutet and the University of Copenhagen. Nationally, it works closely with other K.G. Jebsen Medical Research Centres, such as those for Parkinson's disease and neuropsychiatric disorders. Industrial partnerships with pharmaceutical companies like Roche and Biogen facilitate access to experimental compounds and advanced diagnostic tools for clinical studies.

Funding and the K.G. Jebsen Foundation

Core funding is provided by the K.G. Jebsen Foundation, established from the fortune of Kjell Inge Røkke. The foundation's endowment supports several designated medical research centres for an initial ten-year period, promoting long-term, ambitious research programs. This stable funding is supplemented by competitive grants from the Research Council of Norway, the European Union's Framework Programmes for Research and Innovation, and charitable organizations like the Norwegian Health Association. This diversified financial model ensures the centre's sustainability and capacity to pursue high-risk, high-reward scientific inquiries.

Category:Medical research institutes in Norway Category:Alzheimer's disease research Category:University of Bergen